Tonix partnerships

Just a quick reminder of all the impressive pipeline and partnerships Tonix has.

These collaborations with prestigious institutions demonstrate their commitment to advancing healthcare innovation and tackling critical medical challenges.

• TNX-1500: Partnering with Massachusetts General Hospital and Harvard Medical School to develop treatments for allograft rejection.

• TNX-1300: Working with Columbia University and the National Institute on Drug Abuse (NIDA) to address cocaine intoxication.

• TNX-102 SL: Collaborating with the U.S. Department of Defense and the University of North Carolina at Chapel Hill to tackle acute stress disorder.

• TNX-1800: Developing a COVID-19 vaccine in partnership with the National Institute of Allergy and Infectious Diseases (NIAID).

• TNX-2900: Advancing treatments for Prader-Willi syndrome with Inserm Transfert, CHU de Toulouse, and Aix-Marseille Université.

• TNX-4200: Creating broad-spectrum antiviral solutions in collaboration with the U.S. Department of Defense and the Defense Threat Reduction Agency (DTRA).

I’ve been investing in pharma and biotech for over a decade, experiencing both gains and losses along the way. While it’s true that this company is still dealing with the lingering effects of past challenges, such as over-dilution, reverse splits, Nasdaq compliance issues, and financial struggles, it stands out in one significant way. There are countless pharma/biotech stocks with valuations of $200M, $300M, or even $400M that don’t come anywhere close to having the robust pipeline that Tonix does.

I believe that if a big pharma comes in for partnership, the price share will really explode.

Long life to Tonix, and might bring more health to people who need it (and help us pay off our mortgages🤓)